Agreed! Kind of far out. Not thrilled with the.
Post# of 148278
Not thrilled with the...."update on the ongoing discussions with the FDA and the U.K. Medicines & Healthcare product Regulatory Agency (MHRA) for leronlimab as a treatment for COVID-19"
Looks like will once again be waiting, and hoping for a response by either the FDA or MHRA. I'm not looking forward to how the rest of the market interprets that. Likely have a string of red days going into the conference based on history. Would rather have had no announcements until something definitive could be released, rather than just more "updates."